Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid. (24th May 2011)

• Record Type: Journal Article
• Authors: Luis, Cheryl A.; Abdullah, Laila; Ait-Ghezala, Ghania; Mouzon, Benoit; Keegan, Andrew P.; Crawford, Fiona; Mullan, Michael
• Other Names: Urakami Katsuya Academic Editor.
• Is Part Of: International journal of alzheimer's disease. Volume 2011(2011)
• Publication Date: 2011-05-24
• Subjects: Alzheimer's disease -- Periodicals; 616.831005
• DOI: 10.4061/2011/786264
• Languages: English
• ISSNs: 2090-8024

Abstract

Abstract : We examined the usefulness of brief neuropsychological tests and serum A β as a predictive test for detecting MCI/AD in older adults. Serum A β levels were measured from 208 subjects who were cognitively normal at enrollment and blood draw. Twenty-eight of the subjects subsequently developed MCI (n=18 ) or AD (n=10 ) over the follow-up period. Baseline measures of global cognition, memory, language fluency, and serum A β 1–42 and the ratio of serum A β 1–42 /A β 1–40 were significant predictors for future MCI/AD using Cox regression with demographic variables, APOE ε 4, vascular risk factors, and specific medication as covariates. An optimal sensitivity of 85.2% and specificity of 86.5% for predicting MCI/AD was achieved using ROC analyses. Brief neuropsychological tests and measurements of A β 1–42 obtained via blood warrants further study as a practical and cost effective method for wide-scale screening for identifying older adults who may be at-risk for pathological cognitive decline.